8247 (8247) Fair Value & Analysis

Healthcare · Market cap HK$407M

8 8247 8247 · HK

PriceHK$2.81

Fair ValueHK$1.45

Upside-48.4%

Quality49/100

Watch 8247 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$1.08 – HK$2.16

Fair value as of: Jul 3, 2026

From 1 valuation models · updated today

Share price −5.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.5700 – HK$6.19 · fair‑value band HK$1.08 – HK$2.16 · the HK$2.81 price screens above the HK$1.45 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

8247 (8247) currently trades at HK$2.81, while our model-based Fair Value estimate is HK$1.45 — implying the stock looks roughly 48.4% overvalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 8247 generated revenue of HK$184M at a net margin of -27.8%. Revenue declined 31.5% year over year. It earns a return on equity of -45.2%. Net debt stands at HK$117M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$184M

Revenue growth (YoY) -31.5%

Net margin -27.8%

Return on equity -45.2%

Free cash flow −HK$32.6M FY2025

Operating margin -40.2%

More key figures

EPS (TTM) HK$-0.1200

EPS growth (YoY) +554%

Net debt HK$117M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

8247 reported revenue of HK$184M in FY2025 versus HK$348M in FY2021, a compound −14.7%/yr. Reported net income was −HK$51.1M in FY2025.

Revenue −14.7%/yr

FY21 HK$348M

FY22 HK$373M

FY23 HK$289M

FY24 HK$263M

FY25 HK$184M

Net income

FY21 −HK$1.1M

FY22 HK$8.1M

FY23 −HK$11.6M

FY24 −HK$42.5M

FY25 −HK$51.1M

Is 8247 fairly valued? → Check now

Similar stocks

6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$472.80	$190.31	-60%
Danaher Corporation DHR	$186.64	$85.95	-54%
2359 2359	HK$152.80	HK$120.99	-21%
WuXi AppTec Co WUXAY	$18.59	$25.09	+35%
IDEXX Laboratories, Inc IDXX	$545.73	$255.77	-53%
Lonza Group LZAGY	$63.74	$25.98	-59%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 8247 (8247) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$1.45 versus a price of HK$2.81 — about −48% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 8247?

Our model-based fair value for 8247 is HK$1.45 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$2.81.

What is the quality score of 8247?

8247 has a Quality Score of 49/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 8247 (8247)?

8247 reported trailing-twelve-month revenue of about HK$184M (latest available figure, as of Jul 3, 2026).

What is the net profit margin of 8247?

The net profit margin of 8247 is about -27.8%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.